SGYP Synergy Pharmaceuticals, Inc.

3.48
-0.21  -6%
Previous Close 3.69
Open 3.60
Price To book 7.99
Market Cap 782.82M
Shares 224,949,000
Volume 7,683,160
Short Ratio 8.86
Av. Daily Volume 5,833,880

SEC filingsSee all SEC filings

  1. 8-K - Current report 17874772
  2. 8-K - Current report 17832119
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17831210
  4. 8-K - Current report 17825321
  5. 8-K - Current report 17820633

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data from first and second trials met primary endpoints - December 9 and 22, 2016. sNDA filing submitted March 24, 2017. Estimate 10-month review, rendering a PDUFA date of January 24, 2018.
Trulance (plecanatide)
Constipation-predominant irritable bowel syndrome (IBS-C)
Approved January 19, 2017.
Trulance (plecanatide)
Chronic idiopathic constipation (CIC)
Phase 1b data released January 2016. Phase 2 planned.
Dolcanatide
Mild-to-moderate ulcerative colitis

Latest News

  1. Allergan's Irritable Bowel Drug Viberzi Approved in Canada
  2. What Do the Ardelyx Numbers Mean for the Company?
  3. Synergy Pharmaceuticals and Durect Corporation Both Sail Higher on Trader Optimism
  4. Synergy Pharma reports 1Q loss
  5. Synergy Pharmaceuticals Reports First Quarter 2017 Financial Results and Business Update
  6. Synergy Scores Again: Trulance Product Meets Phase 3 Endpoints In Second Indication
  7. Synergy Pharmaceuticals to Present Positive TRULANCE™ (Plecanatide) Phase 3 Data at Digestive Disease Week (DDW) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
  8. Synergy Pharmaceuticals to Present TRULANCE™ (Plecanatide) Phase 3 Data at Digestive Disease Week (DDW) for the Treatment of Adults with Chronic Idiopathic Constipation (CIC) with Moderate to Very Severe Bloating
  9. Synergy Presents New Insights at Digestive Disease Week (DDW) Examining Patient and Physician Perceptions and Experiences with Chronic Idiopathic Constipation (CIC)
  10. Synergy Pharmaceuticals to Highlight New Data for TRULANCE™ (Plecanatide) at Digestive Disease Week (DDW)
  11. Synergy Pharmaceuticals to Present at the 42nd Annual Deutsche Bank Healthcare Conference
  12. Synergy Pharmaceuticals Appoints Gary G. Gemignani as Chief Financial Officer
  13. Biotech Movers: Synergy, Biogen, Insys
  14. Biotech Movers: Neurocrine Biosciences Leaps on Drug Approval, Synergy Pharma Issued Three Patents
  15. Synergy Pharmaceuticals Announces Issuance of Three New Patents Expected to Extend TRULANCE™ (Plecanatide) Patent Protection Until 2032
  16. [$$] Overheard
  17. Drug Company's New Poop Emojis Make a Splash
  18. Trevena, Synergy Lead Biotech Movers
  19. Synergy Pharmaceuticals Launches the Poop Troop, the First Emoji Keyboard Designed to Support Dialogue Around Chronic Idiopathic Constipation (CIC)
  20. SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Synergy Pharmaceuticals Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

SEC Filings

  1. 8-K - Current report 17874772
  2. 8-K - Current report 17832119
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17831210
  4. 8-K - Current report 17825321
  5. 8-K - Current report 17820633
  6. 8-K - Current report 17809629
  7. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17796750
  8. DEF 14A - Other definitive proxy statements 17796408
  9. 8-K - Current report 17777256
  10. PRE 14A - Other preliminary proxy statements 17765242